24May 2018

THE EFFECT OF A NEW PROBIOTIC PRODUCT LINE IN PATIENTS WITH IRRITABLE BOWEL SYNDROME: CLINICAL OBSERVATION.

  • Clinic of Gastroenterology; ?Tsaritsa Yoanna ?ISUL? University Hospital, Medical University of Sofia, Bulgaria.
Crossref Cited-by Linking logo

  • Abstract
  • References
  • Cite This Article as
  • Corresponding Author

Background It has been proven for many years that probiotics play pivotal role in the treatment of IBS patients. However it is still not very clear which strains are more beneficial than others in the treatment of irritable bowel syndrome (IBS).Our aim in the current clinical observation was to follow up the effect of a novel probiotic product line available on the Bulgarian market - Biopron IB-Symbio (Walmark, Czech Republic) in the treatment of IBS patients. Methods This prospective clinical observation included 45 consecutive patients divided into three groups: group 1 – 15 patients with diarrhea predominant post-infectious IBS (IBS-D), group 2 - 15 with constipation-predominant IBS (IBS-C) and group 3 – 15 IBS patients meeting Rome III but not meeting Rome IV criteria. Four week monotherapy with a new probiotic line was commenced in every group. The symptoms were evaluated before and after treatment. Moreover in IBS-D group fecal calprotectin (FCP) was monitored Results Significant reduction of FCP mean levels was observed in group 1 – from 152 µg/g at week 0 to 64 µg/gat week 4 (p<0,001). After probiotic treatment diarrhea was present only in 3 (20%) patients, and pain in 5 (33%) of the patients. In group 2 constipation was present after treatment just in 2 (13%) patients and abdominal pain in 4 (27%) of them. In group 3 - at 4 week after treatment discomfort was present in 3 (20%) patients, bloating in 2 (13%) patients and change in frequency of stool in 4 (27%) Conclusion The current clinical observation shows that Biopron probiotic product line significantly improves the symptoms in IBS patients. Moreover, it reduces the inflammatory activity in patients with post-infectious IBS.Additional multicenter observations with larger number of patients from different regions are needed to obtain even more accurate data

  1. Spinelli A. Irrirable bowel syndrome. Clin Drug Invest 2007: 27 (1): 15-33
  2. Сamilleri M, Dubois D, Coulie B, et al. Prevalence and socioeconomic impact of upper gastrointestinal disorders in the United States: Results of the US Upper Gastrointestinal Study. Clin Gastroenterol. Hepatol. 2005;3:543-552.
  3. Drossman DA. The Rome IV Committees, editor. History of functional gastrointestinal symptoms and disorders and chronicle of the Rome Foundation. In: Drossman DA, Chang LC, Kellow WJ, Tack J, Whitehead WE, editors.?Rome IV functional gastrointestinal disorders: disorders of gut-brain interaction. Raleigh, NC: The Rome Foundation; 2016. pp. 549?576.
  4. Moayyedi P, Mearin F, Azpiroz F, et al. Irritable bowel syndrome diagnosis and management: A simplified algorithm for clinical practice. UEG Journal. 2017; 5(6): ?773-788.
  5. Nakov VN, Gerova VA, Nakov RV. Fecal Calprotectin is a reliable non-invasive marker for assessment of intestinal inflammation in patients with irritable bowel syndrome. Compt rend Acad Bulg Sci, 66, 2013, 9, 1339-1344
  6. Drossman DA, moderator. AGA Clinical Symposium - Rome III: New Criteria for the Functional GI Disorders. Program and abstracts of Digestive Disease Week; May 20-25, 2006; Los Angeles, California. [Sp461-469]
  7. Patcharatrakul Т. et al Application of Rome III vs. Rome IV Diagnostic Criteria for Irritable Bowel Syndrome (IBS) in Clinical Practice: is the Newer the Better? Gastroenterology. 152. S717. 10.1016/S0016-5085(17)32494-0.
  8. Simr?n, M, T?rnblom, H, Palsson, OS Management of the multiple symptoms of irritable bowel syndrome. Lancet Gastroenterol Hepatol 2017; 2: 112?122.
  9. Ford, AC, Quigley, EM, Lacy, BE Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: Systematic review and meta-analysis. Am J Gastroenterol 2014; 109: 1547?1561. quiz 1546, 1562.
  10. B?hlmann Laboratories AG. Quantum Blue Calprotectin: Quantitative lateral flow assay [pamphlet]. Sch?nenbuch: B?hlmann Laboratories AG; 2009.
  11. Velikova T., Nakov V, Georgieva R, Toumangelova-Yuzeir K, Ivanova-Todorova E, Nakov R et al. Immunomodulating properties of a novel synbiotic on healthy persons. Compt rend Acad Bulg? Sci, 68, 2015, 10, 1321-1326.
  12. Curro D, Ianiro G, Pecere S, Bibbo S, Cammarota G. Probiotics, fi bre and herbal medicinal products for functional and infl ammatory bowel disorders. Br J Pharmacol 2016; doi: 10.1111/bph. 13632
  13. Silk DBA, Davis A, Vulevic J, Tzortzis G, Gibson GR. Clinical trial: the eff ects of a trans-galactooligosaccharide prebiotic on faecal microbiota and symptoms in irritable bowel syndrome. Aliment Pharmacol Ther 2009; 29(5): 508-18
  14. Guglielmetti S, Mora D, Gschwender M, Popp K. Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life--a double-blind, placebo-controlled study. Aliment Pharmacol Ther. 2011 May;33(10):1123-32
  15. Fenn GC, Wilkinson PD, Lee CE, Akbar FA. A general practice study of the efficacy of Regulan in functional constipation. Br J Clin Pract. 1986 May;40(5):192-7.
  16. Moayyedi, P, Quigley, EM, Lacy, BE The effect of fiber supplementation on irritable bowel syndrome: A systematic review and meta-analysis. Am J Gastroenterol 2014; 109: 1367?1374
  17. Colecchia A, Vestito A, La Rocca A, Pasqui F, Nikiforaki A, Festi D. Eff ect of a symbiotic preparation on the clinical manifestations of irritable bowel syndrome, constipation-variant. Results of an open, uncontrolled multicenter study. Minerva Gastroenterol Dietol 2006; 52(4): 349-58
  18. Palsson et al. Population prevalence of Rome IV and Rome III Irritable Bowel Syndrome in the US, Canada and UK. DDW 2016. Mon 1642.
  19. Suarez F, Levitt MD, Adshead J, Barkin JS. Pancreatic supplements reduce symptomatic response of healthy subjects to a high fat meal. Dig Dis Sci 1999; 44(7):1317-21
  20. Leeds JS, Hopper AD, Sidhu R, Simmonette A, Azadbakht N, Hoggard N, Morley S, Sanders DS. Some Patients With Irritable Bowel Syndrome May Have exocrine Pancreatic Insufficiency. Clin Gastroenterol Hepatol 2010; 8: 433-438

[Ventsislav Nakov and Radislav Nakov. (2018); THE EFFECT OF A NEW PROBIOTIC PRODUCT LINE IN PATIENTS WITH IRRITABLE BOWEL SYNDROME: CLINICAL OBSERVATION. Int. J. of Adv. Res. 6 (May). 1001-1006] (ISSN 2320-5407). www.journalijar.com

Radislav Nakov
Clinic of Gastroenterology; “Tsaritsa Yoanna –ISUL“ University Hospital, Medical University of Sofia, Bulgaria

DOI:

Article DOI: 10.21474/IJAR01/7122      
DOI URL: https://dx.doi.org/10.21474/IJAR01/7122

Download Full Paper

Download PDF No. of Downloads: 15 | No. of Views: 95